Increased serum levels of C3 and C4 in patients with schizophrenia compared to eutymic patients with bipolar disorder and healthy controls. Rev Bras Psiquiatr. 2012;34:119–20. Google Scholar Boyajyan A, Khoyetsyan A, Chavushyan A. Alternative complement pathway in schizophrenia. Neurochem ...
As with any targeted therapy, ALK-driven NSCLC tumor cells inevitably acquire drug resistance, leading to clinical relapse. At the present time, ALK inhibitors have not yet been approved for use in other ALK-driven cancers than NSCLC; however, some studies have reported remarkable responses, and...